drugset / Trial / NCT03396874

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT03396874

Phase 2 Completed 1435 enrolled University of Michigan
NaSingle-groupOpen-labelDiagnostic

Summary

This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells. Together with a PET/CT scanner, the distribution of 68Ga-PSMA can be determined in the body. To test this new drug, participants will receive an intravenous injection of Ga-68-PSMA and then have a PET/CT scan. The scan results will be made available to study participants and treating physicians.

Timeline

Start
2018-02-09
Primary completion
2022-08-09
Completion
2022-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 68Ga-PSMA-11 Diagnostic / imaging agent 185 mbq Intravenous